A study to evaluate the efficacy of Eribulin retreatment in HER2 negative Metastatic Breast Cancer patients - Phase II study
Phase 2
- Conditions
- HER2-negative metastatic breast cancer
- Registration Number
- JPRN-UMIN000027165
- Lead Sponsor
- Toho university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patient with active infection 2.Pregnant, lactating, or intends to become pregnant 3.brain metastasis with clinical symptoms 4.Physician concludes that the patient's participation in this trial is inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method